This document discusses new data on non-vitamin K antagonist oral anticoagulants (NOACs) from clinical trials and real-world use. It summarizes findings from trials on the use of direct oral anticoagulants (DOACs) in addition to antiplatelet therapy for acute coronary syndrome. DOACs were associated with lower risk of the primary efficacy endpoint in ST-elevation myocardial infarction but not in non-ST-elevation acute coronary syndrome, and were linked to higher risk of major bleeding. Specific antidotes have been developed for NOACs that allow rapid and complete reversal of their anticoagulant effects. Low doses of NOACs may be useful for secondary prevention after STE